Answers are grounded in this paper and cite their sources.
Low- or very low-certainty evidence suggests that exenatide may improve motor impairment for people with PD. The difference in motor impairment observed between groups may persist for some time following cessation of exenatide. This raises the possibility that exenatide may have a disease-modifying effect. SAEs were unlikely to be related to treatment. The effectiveness of exenatide for improving HRQoL, non-motor outcomes, ADLs, and psychological outcomes is unclear. Ongoing studies are assessing other GLP-1 receptor agonists.
No takes yet. Share an insight, caveat, or question.
Mulvaney et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: